Kimi K3 Is So Hot It Broke the Servers: Why China's AI Sensation Just Had to Stop Selling Subscriptions

 Kimi K3 Is So Hot It Broke the Servers: Why China's AI Sensation Just Had to Stop Selling Subscriptions

## The 2.8 trillion-parameter "open-weight" model attracted so many users in 48 hours that its GPUs simply couldn't keep up. Here's what the unprecedented "sold out" moment means for the global AI race.

---

### The "Sold Out" Sign That Shocked the Tech World

In a move that underscores just how ravenous the demand for cutting-edge AI has become, Chinese startup Moonshot AI has done something almost unheard of: **it has temporarily stopped selling new subscriptions to its flagship Kimi K3 model.**

On July 19, 2026—just three days after the model's launch—the company announced it was pausing new consumer subscriptions because user demand had "pushed close to the limits of our current capacity."

"Over the past 48 hours, demand has pushed close to the limits of our current capacity," the company stated. "Our GPUs [graphics processing units] are feeling it."

For a startup that had just demonstrated it could rival the world's best, it was both a triumph and a crisis. The triumph: global demand was overwhelming. The crisis: China's ongoing compute shortage had just become a very public problem.

---

### What Is Kimi K3?

Kimi K3 is not just another large language model. It represents a fundamental shift in the global AI landscape.

| Feature | Specification |

|---------|---------------|

| **Parameters** | **2.8 trillion** (the world's largest open-weight model) |

| **Context Window** | **1 million tokens** |

| **Architecture** | Sparse mixture-of-experts (896 experts, 16 activated per inference) |

| **Capabilities** | Native visual understanding, optimized for software engineering, knowledge work, and complex reasoning |

| **Performance** | Outperforms all rivals except Anthropic's Claude Fable 5 and OpenAI's GPT-5.6 Sol |

The model is **open-weight**, meaning its parameters will be available for users to download and customize starting **July 27, 2026**—making it the world's largest open-weight frontier model.

Within hours of its release, Kimi K3 topped Arena AI's ranking for front-end code development—the first Chinese model to achieve that feat.

---

### Why the Subscription Pause? The 48-Hour Capacity Crunch

The scale of the demand was staggering. Within 48 hours of its launch, the surge in traffic had "pushed close to the limits of our current capacity" and "approached the limits of our existing compute cluster."

**The problem isn't just about raw demand—it's about the hardware required to serve it.**

Kimi K3 is a massive model. Its 2.8 trillion parameters, even compressed, require nearly **3 terabytes of memory** just to load. The company recommends deploying the model on a supernode with **64 or more accelerators**—a configuration that demands high-bandwidth interconnect and substantial GPU clusters.

In other words, this isn't a model you run on a laptop. It needs a multi-GPU rig, on the order of **eight H100 or H200 chips just to serve it.**

**The "open-weight" paradox:** While Kimi K3 is billed as open-weight—meaning anyone should be able to download and run it themselves—Moonshot isn't releasing the weights until July 27. Until then, the only way to use the model is through Moonshot's own apps and API. All that demand lands on one company's servers.

---

### The Deeper Issue: China's "Compute Poverty"

The Kimi K3 crunch isn't just a company-specific issue—it's a window into the broader challenges facing China's AI industry.

Chinese AI labs continue to face **computing power shortages** as the country's chip industry strives to catch up under U.S. export control measures, which have restricted access to advanced chips and chipmaking equipment.

As one analysis put it, when Kimi K3—a 2.8 trillion-parameter "nuclear-powered aircraft carrier"—launched, Moonshot found that its existing chip inventory simply couldn't support the concurrent inference demands of millions of daily active users.

Ryan Fedasiuk, a fellow at the American Enterprise Institute, noted that while Kimi K3 has helped China shorten its model capabilities gap with the U.S. from months to just weeks, "compute constraints would weigh on their global competitiveness."

"To serve K3 to millions of monthly active users, Moonshot will likely spend **billions of dollars on chips and energy** to power them—chips that Chinese companies still struggle to produce at scale," Fedasiuk wrote.

---

### What Moonshot Is Doing About It

Moonshot isn't standing still. The company has outlined a multi-pronged response:

#### 1. Capacity Expansion

The company is "adding capacity as fast as we can" and will reopen new subscription spots in batches. But capacity expansion takes time—high-end compute clusters take 6-12 months from hardware procurement to deployment.

#### 2. Product Segmentation

Moonshot is splitting its offerings into two tiers: a **Kimi Membership** covering web, app, and Work products, and a **Kimi Code Membership** for programming workflows. This allows the company to allocate compute more precisely and prevent coding workloads—which are compute-intensive—from overwhelming the system.

#### 3. Open-Weight Release

On **July 27, 2026**, Moonshot plans to release Kimi K3's weights publicly. Once the files are public, large customers and cloud providers can host K3 themselves and skip Moonshot's queue.

#### 4. IPO Preparation

The timing is particularly delicate. Moonshot is preparing for a Hong Kong IPO that could value the company at more than **$30 billion** (or $31.5 billion pre-money). The company's annual recurring revenue reached **$300 million in June 2026**, up from $200 million in April.

On the day of K3's launch, Moonshot's ARR reportedly recorded its **largest single-day increase ever**—a signal of the immense demand, even if the company couldn't fully capitalize on it immediately.

---

### The Market Impact: Ripples Across the Industry

Kimi K3's launch has already triggered major fluctuations in global markets:

- **U.S. semiconductor stocks** sold off as investors reassessed the AI competitive landscape

- **Chinese rivals** felt the pressure: Zhipu AI fell 19.57% on Monday after plunging 28.49% on Friday; MiniMax closed 10.60% lower

- **Partners benefited**: Chinasoft's shares closed up 22.97% following a partnership announcement with Moonshot

As Bloomberg noted, the model's release "sent a jolt through markets, forcing investors to reassess some of the biggest assumptions behind the global tech rally."

---

### The Human Element: What This Means for You

**For AI Developers**

If you're eager to try Kimi K3, you're stuck waiting. New consumer subscriptions are paused until capacity expands. Your best bet is to wait for the **July 27 open-weight release** and run the model yourself—if you have the hardware.

**For AI Investors**

The K3 crunch is a reminder that the AI race isn't just about who has the best models. It's about who has the **infrastructure to deploy them**. Companies that can secure compute capacity—whether through domestic supply chains or strategic partnerships—will have a significant advantage.

**For the AI Industry**

The K3 incident is a preview of what's coming. As models get larger and more capable, the infrastructure gap will only widen. The companies that can bridge that gap—through investment, innovation, or policy—will shape the future of AI.

---

### Frequently Asked Questions

**Q: What is Kimi K3?**

Kimi K3 is a **2.8 trillion-parameter** open-weight AI model developed by Chinese startup Moonshot AI. It's the world's largest open-weight model, with a 1 million-token context window and native visual understanding.

**Q: Why did Moonshot pause subscriptions?**

The model became too popular too fast. In the **48 hours after launch**, user requests pushed Moonshot's GPU capacity to its limits. The company paused new consumer subscriptions to protect existing users' experience.

**Q: Is Kimi K3 still available?**

Existing subscribers are **not affected**. New consumer subscriptions are paused. The API remains available, but capacity is constrained. Moonshot says it will reopen subscriptions in batches as it adds capacity.

**Q: When will the model weights be released?**

Moonshot plans to release Kimi K3's weights publicly on **July 27, 2026**.

**Q: Is this a sign that China is catching up in AI?**

Yes and no. Kimi K3 demonstrates that Chinese labs can match or beat U.S. models on some benchmarks. But the compute crunch shows that China still faces significant infrastructure challenges due to U.S. export controls on advanced chips.

**Q: What does this mean for Moonshot's IPO?**

The timing is delicate. Moonshot is preparing for a Hong Kong IPO targeting a valuation above $30 billion. The capacity crunch is a negative headline, but it also demonstrates overwhelming demand—which could be a positive signal for investors.

**Q: What is the "open-weight paradox"?**

Kimi K3 is billed as open-weight, but Moonshot isn't releasing the weights until July 27. Until then, the only way to use the model is through Moonshot's own servers—creating a bottleneck that defeats the purpose of open source.

---

### Conclusion: The Double-Edged Sword of Success

Moonshot AI's Kimi K3 subscription pause is a classic "good problem to have"—but it's still a problem. The model's overwhelming popularity has exposed the fragility of China's AI infrastructure, even as it demonstrates the country's growing capabilities.

The incident reveals three critical truths:

**First**, Chinese AI labs can now build models that compete with the world's best. Kimi K3's performance on coding benchmarks proves that.

**Second**, the infrastructure to deploy these models at scale is still catching up. The compute gap is real, and it's widening.

**Third**, the AI race is no longer just about who has the best models—it's about who has the infrastructure to serve them.

For Moonshot AI, the next few weeks will be critical. The company needs to add capacity, manage user expectations, and navigate a high-stakes IPO—all while competitors watch closely.

For the rest of the AI world, the "Kimi crunch" is a warning: the models are getting better faster than the infrastructure to support them. The companies that can solve that equation will define the next era of AI.

-Read more from moon light--

### Disclaimer

**IMPORTANT:** This article is for informational and educational purposes only and does not constitute financial, investment, legal, or professional advice. The information contained herein is based on publicly available sources and reflects the author's understanding as of the publication date. Moonshot AI's subscription policies, IPO plans, and capacity expansion efforts are subject to change. You should consult with qualified professionals before making any decisions based on this information. All investments carry risk, including the potential loss of principal.

---

*Published: July 21, 2026*

-Read more--

**Tags:** Kimi K3, Moonshot AI, AI compute shortage, Chinese AI, open-weight model, AI infrastructure, GPU shortage, AI startup, Hong Kong IPO, AI capacity crunch, large language model, US-China AI rivalry, AI deployment, compute cluster, AI scalability, 2.8 trillion parameters, AI subscription pause, AI demand surge

GM's Comeback Quarter: Why the Automaker Just Raised Guidance for the Second Time in 2026

 GM's Comeback Quarter: Why the Automaker Just Raised Guidance for the Second Time in 2026

**The Big Three stalwart just delivered a Q2 earnings beat that silenced the skeptics. Here's how GM is defying the headwinds—and what it means for your portfolio.**

---

## Introduction: The "Silent Comeback" You Missed

While the media was fixated on the chip selloff and the AI trade, General Motors quietly delivered one of its strongest quarters in recent memory.

On July 21, 2026, GM reported second-quarter results that blew past Wall Street expectations—and then raised its full-year guidance for the second time this year. Adjusted earnings per share came in at **$3.57**, well above the consensus estimate of $3.18. Revenue hit **$48.03 billion**, up 1.9% year-over-year—marking the first year-over-year revenue growth since the first quarter of 2025.

And yet, shares dipped 3.3% following the release. Why? Because in today's market, even a beat can be met with skepticism.

But for investors willing to look past the immediate noise, GM's Q2 report tells a story of a company that is quietly transforming itself—cutting costs, narrowing EV losses, and leveraging its dominant position in trucks and SUVs to generate record profits.

---

## The Numbers That Matter: A Quarter to Remember

Let's break down what GM actually delivered.

### Q2 2026 Results at a Glance

| Metric | Q2 2026 | Consensus | Year-over-Year |

|--------|---------|-----------|----------------|

| **Revenue** | $48.03B | $47.01B | **+1.9%** |

| **Adjusted EPS** | $3.57 | $3.20 | **+41%** |

| **Adjusted EBIT** | $3.94B | $3.7B | **+31%** |

| **Adjusted EBIT Margin** | 8.2% | — | +180 bps |

The numbers tell a clear story: GM is making more money on fewer sales. U.S. vehicle deliveries slipped 4.2% to about 715,000 vehicles during the quarter. But profitability surged because GM is selling more profitable vehicles—trucks and SUVs—at stable prices while controlling costs.

**"Customer demand in North America remains strong driven by our very attractive lineup of pickups and SUVs,"** CEO Mary Barra wrote in her letter to shareholders.

### North America: The Profit Engine

GM North America remained the company's largest earnings contributor, generating adjusted EBIT of **$3.4 billion** with an **8.6% margin**—up from $2.4 billion and a 6.1% margin in the prior-year period. That's a 2.5 percentage point improvement in margin year-over-year.

**The key drivers:**

- **Lower warranty costs**: GM is spending less on repairs and recalls

- **Reduced EV losses**: The company's electric vehicle division is bleeding less cash

- **Increased operating efficiency**: Streamlined operations across the board

- **Stable pricing**: Average transaction price held at $52,000

Barra put it simply: **"Our 8.6% EBIT-adjusted margin in North America was up 2.5 points from a year ago, and we continue to lower our warranty costs, reduce EV losses, and increase operating efficiency"**.

---

## The Guidance Raise: A Vote of Confidence

For the second time in 2026, GM raised its full-year guidance. The new targets reflect management's confidence that the profitability improvements are sustainable.

### Updated 2026 Guidance

| Metric | New Guidance | Prior Guidance | Change |

|--------|--------------|----------------|--------|

| **Adjusted EBIT** | $14.0–$16.0B | $13.5–$15.5B | **+$0.5B** |

| **Adjusted EPS** | $12.00–$14.00 | $11.50–$13.50 | **+$0.50** |

| **Adj. Auto FCF** | $9.5–$11.5B | $9.0–$11.0B | **+$0.5B** |

The midpoint of the new EPS range ($13.00) sits above the analyst consensus of $12.79. Adjusted automotive free cash flow guidance was also raised to $9.5 billion to $11.5 billion.

GM's updated guidance is built on several key assumptions:

- **Pricing**: Up around 0.5%

- **EV losses**: Improving by $1.0 to $1.5 billion

- **Regulatory benefits**: $500 to $700 million

- **Gross tariff costs**: $2.5 to $3.5 billion

- **Commodity inflation**: $1.5 to $2.0 billion (including DRAM)

**The tariff story is particularly noteworthy.** Last year, GM's Q2 EBIT was weighed down by tariff costs. Those costs are now easing as tariff offsets take hold and GM has spent the past year reworking its supply chain, shifting production, and negotiating with suppliers to blunt the tariff hit.

---

## The EV Pivot: Narrowing Losses, Not Abandoning the Future

One of the most significant developments in GM's Q2 report is the progress on electric vehicles.

GM has been retreating from its aggressive EV spending—a move that has involved **$10.9 billion in charges since late last year**. The company has paid $4.5 billion of an expected $7.2 billion in cash charges tied to the pullback through Q2.

But the pain is starting to pay off.

**GM now expects EV losses to improve by $1 billion to $1.5 billion this year versus fiscal 2025**. The company is shrinking its losses while maintaining its position as the **No. 2 EV seller in the U.S.** behind Tesla.

GM indicated it has largely wrapped up the accounting charges associated with its EV retreat. The cumulative bill has been heavy, but the worst appears to be behind the company.

As one analyst put it, GM is "continuing to unwind a multibillion-dollar EV pullback". The company is becoming more disciplined about where it invests—focusing on profitable segments while trimming losses in less promising areas.

---

## The Dividend and Shareholder Returns

GM's board declared a quarterly cash dividend of **$0.18 per share** on its common stock, payable September 17 to shareholders of record as of September 4.

While modest, the dividend signals confidence in the company's cash flow generation. Adjusted automotive free cash flow surged **78% year-over-year to $5.0 billion** during the quarter. Automotive operating cash flow increased 9% to $5.1 billion.

---

## What the Analysts Are Saying

Wall Street remains optimistic about GM's trajectory.

- **JPMorgan analyst Ryan Brinkman** maintained an Overweight rating and boosted the price target from $98 to $110.

- **UBS** has a $102 price target, reflecting optimism about the company's diversification efforts.

- Analysts rate the stock a **Buy**, with a mean price target of **$95.85**, implying 26% upside from the current share price.

JPMorgan had predicted GM would "modestly beat EBIT expectations" for Q2, and that's exactly what happened. The bank saw a comeback coming after GM's 7% year-to-date decline.

---

## The Human Element: What This Means for You

### For GM Employees

The Q2 results are a validation of the hard work and cost-cutting measures implemented across the company. GM cut 500 to 600 salaried IT jobs earlier this year as part of a broader workforce restructuring. Those moves are paying off in the form of improved margins and profitability.

### For American Consumers

GM's stable pricing—with average transaction prices holding at **$52,000**—suggests that the company isn't engaging in destructive price wars. Incentives as a percentage of MSRP averaged just 4.7% in Q2, below the industry average of 6.3%.

That's good news for GM's bottom line, but it also means vehicle prices are staying high. Affordability remains a headwind as elevated prices and interest rates continue to weigh on consumers.

### For Investors

GM's Q2 report is a reminder that the company is not just a "legacy automaker" struggling to transition. It's a profitable, cash-generating machine that is quietly executing on a disciplined strategy. The 3.3% dip in the stock following the report may present a buying opportunity for investors who believe in the turnaround.

---

## The Risks to Watch

No investment is without risk, and GM faces several headwinds:

**1. Slowing U.S. sales.** GM sold approximately 715,000 vehicles in the U.S. in Q2, a 4.2% decline from a year ago. Much of the drop was due to discontinued models like the Cadillac XT4 and XT6 and the Chevrolet Malibu, as well as the EV pullback. But the trend bears watching.

**2. Tariff uncertainty.** While tariffs are easing, GM still expects gross tariff costs of $2.5 to $3.5 billion for the full year. Any escalation in trade tensions could reverse the progress.

**3. EV transition.** While EV losses are narrowing, the transition to electric vehicles remains costly and uncertain. GM's EV sales have fallen sharply following the expiration of the federal EV tax credit.

**4. Commodity inflation.** GM expects commodity inflation—including DRAM—of $1.5 to $2.0 billion. Semiconductor costs remain elevated.

---

## Frequently Asked Questions

### Q: How did GM perform in Q2 2026?

GM reported adjusted earnings of **$3.57 per share** on revenue of **$48.03 billion**, both beating analyst expectations. Adjusted EBIT rose 29.8% to $3.94 billion.

### Q: Why did GM raise its full-year guidance?

GM raised its guidance for the second time in 2026 due to stronger-than-expected profitability in North America, lower warranty costs, narrowing EV losses, and easing tariff pressures.

### Q: What is GM's new EPS guidance?

GM now expects adjusted EPS of **$12.00 to $14.00** for the full year 2026, up from $11.50 to $13.50 previously.

### Q: How are GM's EV losses improving?

GM expects EV losses to improve by **$1 billion to $1.5 billion** this year versus fiscal 2025. The company has largely wrapped up the accounting charges associated with its EV retreat.

### Q: Why did GM stock fall after the earnings beat?

Shares fell 3.3% following the results, reflecting a pattern in the current market where even strong earnings are met with skepticism. Some investors may be concerned about slowing sales or the ongoing EV transition costs.

### Q: What did CEO Mary Barra say?

Barra said: **"Customer demand in North America remains strong driven by our very attractive lineup of pickups and SUVs. Our 8.6% EBIT-adjusted margin in North America was up 2.5 points from a year ago"**.

---

## Conclusion: A Comeback in Progress

General Motors' Q2 2026 earnings report is a testament to the power of disciplined execution. In an environment of slowing sales, tariff uncertainty, and costly EV transitions, GM delivered its strongest quarter in years.

The company's North American operations are firing on all cylinders, with an 8.6% EBIT-adjusted margin that would be the envy of most industrial companies. EV losses are narrowing. Tariff costs are easing. And management has raised guidance twice in 2026.

Yes, there are risks. Sales are slipping. The EV transition remains expensive. And commodity costs are rising. But GM is proving that it can generate substantial profits even in a challenging environment.

As the company continues to unwind its EV pullback and focus on its most profitable segments, the path to sustainable, long-term profitability is becoming clearer.

**For investors willing to look past the noise, GM's Q2 report is a reminder that the company is not just surviving—it's thriving.**

---

## Disclaimer

**IMPORTANT:** This article is for informational and educational purposes only and does not constitute financial, investment, or trading advice. The information contained herein is based on publicly available sources and reflects the author's understanding as of the publication date. Market conditions, stock prices, and company performance are subject to rapid change. Past performance is not indicative of future results. All investments carry risk, including the potential loss of principal. You should consult with a qualified financial advisor before making any investment decisions. The views expressed in this article are those of the author and do not constitute a recommendation to buy or sell any security.

---

*Published: July 21, 2026*

---Read more

**Tags:** General Motors, GM earnings, Q2 2026 earnings, Mary Barra, automotive stocks, GM guidance, electric vehicles, EV losses, North American auto sales, GM stock, dividend stocks, auto industry, tariff costs, GM financial results, investing

Jamie Dimon Won’t Put More of His Own Money Into the Long End of the Bond Market Right Now—Thanks to the $39 Trillion National Debt

 Jamie Dimon Won’t Put More of His Own Money Into the Long End of the Bond Market Right Now—Thanks to the $39 Trillion National Debt

**The most powerful banker on Wall Street just gave a stark warning to anyone holding long-term U.S. government debt. Here's why he's staying away—and what it means for your portfolio.**

---

## The $39 Trillion Elephant in the Room

J.P. Morgan Chase CEO Jamie Dimon has spent years warning policymakers about the dangers of America's ballooning national debt. They haven't listened. Now, he's putting his money where his mouth is—by keeping it out of the long end of the bond market.

In a recent appearance on the *Master Investor* podcast, Dimon was asked whether he would be a buyer of long-dated government bonds at current prices. His answer was characteristically blunt: **"Personally, no."**

The reason? A potential bond market crisis triggered by the U.S.'s $39 trillion national debt—a figure that now costs taxpayers **$24 billion in interest payments every single week**.

"I know that the inflation numbers were good yesterday," Dimon said, referring to the latest CPI data. "The thing about numbers, you dig into these numbers, I mean really dig into them, and I wouldn't give them too much credence."

**When the CEO of the largest bank in America says he won't buy long-term government bonds, every investor should pay attention.**

---

## Why Long Bonds Are a Losing Bet Right Now

### The Math Doesn't Work

Dimon's reasoning is simple, surgical, and devastating. Even if inflation falls to the Federal Reserve's 2% target, he believes the 10-year Treasury yield should still be between **4% and 4.5%**—which is roughly where it sits today.

So where's the upside?

"I don't understand what the upside is," Dimon said flatly.

He went further: the short-term rate should be around **3.25% to 3.5%**, and those levels are "almost there today." In other words, bond prices have already priced in a relatively benign inflation scenario. There's little room for yields to fall—and plenty of room for them to rise.

### The Real Risk: Higher Rates Are Coming

Dimon's core argument is that **persistent U.S. budget deficits will eventually drive interest rates higher** as bond markets demand greater compensation to finance the debt.

"The U.S. is currently operating at a debt-to-GDP ratio of around 120%," he noted. These are numbers that historically only emerge during "a great recession or a depression or a war."

**And yet, the U.S. is "doing quite well."** That's the paradox—and the danger. The economy is resilient, but the debt keeps piling up.

---

## The Human Element: Why This Matters to You

### For the Average American

Dimon's warning isn't just for hedge fund managers. Long-term Treasury yields are the benchmark for mortgages, auto loans, and credit cards. When bond yields rise, borrowing costs rise for everyone.

If Dimon is right—and the bond market eventually forces a reckoning with the $39 trillion debt—**your mortgage could get more expensive. Your car loan could cost more. Your credit card debt could become harder to pay off.**

### For Investors

If you hold long-term bonds or bond funds, Dimon's message is clear: **there's more downside risk than upside potential.** Yields are already close to where they should be even in a best-case scenario. If inflation stays sticky or the deficit continues to balloon, yields could push higher—and bond prices would fall.

### For Policymakers

Dimon has one message for Washington: **deal with it now, or deal with it later under far worse conditions.**

"That would be the far better way to do it," he said of proactive action. "The other way is to wait for it to become a problem, and my guess is that's what's going to happen."

The result? "Higher interest rates, the market getting rattled a little bit, people talking about it constantly—remember the bond vigilantes."

---

## The Professional Perspective: What the Data Shows

| Indicator | Current Status |

|-----------|----------------|

| **U.S. National Debt** | $39+ trillion |

| **Weekly Interest Payments** | $24 billion |

| **Debt-to-GDP Ratio** | ~120% |

| **10-Year Treasury Yield** | ~4-4.5% |

| **Inflation (June 2026)** | 3.5% |

Dimon's caution is rooted in hard numbers. The U.S. is borrowing at a pace that would have been unthinkable a decade ago. And unlike the post-2008 era, there's no easy monetary policy fix—interest rates are already elevated.

**"Even if inflation was 2%, the 10-year bond should probably be at 4-4.5%,"** Dimon said. That means even in a best-case inflation scenario, bond prices have limited upside.

---

## The Bigger Picture: Risks Beneath the Surface

Dimon didn't just warn about bonds. He warned about the entire market.

"I do think those risks are probably bigger than other people think," he said, citing the ongoing conflicts in Ukraine and the Middle East, U.S.-China tensions, and an increase in military expenditure at a time when government deficits are expanding.

On equities, Dimon was similarly cautious. While he would consider an individual stock that represented a strong opportunity, **he would not be a buyer of the broader market at current valuations.**

He acknowledged the global economy has grown more resilient—partly because of lower energy dependence than in previous decades—but warned that **resilience does not rule out a sudden shift.**

"You may need more straws in the camel's back to cause that tipping point," he said.

---

## What This Means for Your Portfolio

### For Bond Investors

Dimon's comments suggest that **long-dated Treasuries are not a smart bet right now.** The potential for yields to rise (and prices to fall) outweighs the modest upside. Consider shorter-duration bonds, which are less sensitive to interest rate changes.

### For Stock Investors

Dimon's warning on equities is more nuanced. He's not saying the market will crash—he's saying the risks are underappreciated. **Diversification and caution are warranted.** He would consider individual stocks, but not the broader market at current valuations.

### For Everyone

The $39 trillion debt isn't going away. Interest payments are consuming a growing share of the federal budget. **At some point, the bond market will force a reckoning.** The question is whether policymakers act before or after that happens.

---

## Frequently Asked Questions

### Q: Why won't Jamie Dimon buy long-term bonds?

Dimon believes that even in a best-case inflation scenario (2%), the 10-year Treasury yield should be around 4-4.5%—which is roughly where it is today. He sees limited upside and significant downside risk from rising yields driven by the $39 trillion national debt.

### Q: What is the U.S. national debt right now?

The U.S. national debt stands at more than **$39 trillion**, with interest payments now costing **$24 billion per week**

### Q: What does the debt-to-GDP ratio tell us?

The U.S. debt-to-GDP ratio is around **120%** —historically, levels that only emerge during wars or deep recessions.

### Q: Should I sell my bond holdings?

Dimon's comments don't necessarily mean you should sell everything. But they do suggest that **long-dated Treasuries carry more risk than reward at current prices.** Consider shorter-duration bonds or diversifying into other asset classes.

### Q: What does Dimon say about stocks?

Dimon would not buy the broader stock market at current valuations. However, he would consider individual stocks that represent a strong opportunity.

### Q: What does "bond vigilantes" mean?

"Bond vigilantes" refers to investors who sell bonds or demand higher yields when they perceive government fiscal policy as irresponsible. Dimon warned that they could return if the debt problem isn't addressed.

---

## Conclusion: A Warning from the Top

Jamie Dimon is not a perma-bear. He runs the largest bank in America. He has a front-row seat to the global economy. And he just told the world that **he won't put more of his own money into the long end of the bond market.**

The reason isn't complicated: the U.S. has $39 trillion in debt, interest payments are soaring, and policymakers are doing nothing about it. Eventually, the market will force the issue—and when it does, bond prices will fall and interest rates will rise.

**"My view is it will become a problem,"** Dimon said.

The question isn't whether he's right. It's whether you're prepared.

---

## Disclaimer

**IMPORTANT:** This article is for informational and educational purposes only and does not constitute financial, investment, or trading advice. The information contained herein is based on publicly available sources and reflects the author's understanding as of the publication date. Market conditions, interest rates, and economic data are subject to rapid change. Past performance is not indicative of future results. All investments carry risk, including the potential loss of principal. You should consult with a qualified financial advisor before making any investment decisions. The views expressed in this article are those of Jamie Dimon and do not necessarily reflect the views of the author or this publication.

---

*Published: July 21, 2026*

Read more---

**Tags:** Jamie Dimon, JPMorgan Chase, long-term bonds, Treasury yields, national debt, $39 trillion debt, bond market, interest rates, inflation, bond vigilantes, investment strategy, fixed income, U.S. Treasury, debt-to-GDP ratio, market risk, bond crisis, federal deficit, government borrowing, portfolio management, Wall Street warning

The $100 Billion GLP-1 War: Inside Novo Nordisk's Explosive Lawsuit Against Eli Lilly Over "Deceptive" Weight-Loss Ads

 The $100 Billion GLP-1 War: Inside Novo Nordisk's Explosive Lawsuit Against Eli Lilly Over "Deceptive" Weight-Loss Ads

## The Danish pharma giant is accusing its American rival of misleading millions of Americans with outdated data. Here's what the legal battle means for patients, investors, and the future of the obesity treatment market.

---

### Introduction: The Shot Heard Round the Pharmaceutical World

On July 21, 2026, the simmering rivalry between the world's two biggest weight-loss drug makers exploded into open legal warfare. Novo Nordisk, the Danish company behind Ozempic and Wegovy, filed a federal lawsuit against Eli Lilly, alleging that the American drugmaker's advertising campaigns for its blockbuster GLP-1 medications—Zepbound and Mounjaro—are "false and materially misleading."

At stake is nothing less than the future of the $100 billion-plus weight-loss drug market. With millions of Americans taking GLP-1 medications and tens of millions more considering them, the outcome of this legal battle could reshape how these life-changing drugs are marketed—and how patients choose between them.

The lawsuit, filed in the U.S. District Court for the District of New Jersey, accuses Lilly of orchestrating a "nationwide pattern of deceptive advertising" that confuses consumers by using "outdated studies" to compare the highest injectable doses of Lilly's medicines against "lower doses of Novo Nordisk's injectable medicines."

Novo Nordisk is seeking a permanent injunction requiring Lilly to pull its advertising and launch a corrective ad campaign. The company has also warned that if Lilly does not voluntarily remove the ads, it will file a formal motion for a preliminary injunction "in the coming days."

**The core allegation?** Lilly's ads are "deliberately simple and deliberately false."

---

## The GLP-1 Revolution: How We Got Here

To understand why this lawsuit matters, you have to understand the drugs at the center of it.

### The Drugs That Changed Everything

GLP-1 receptor agonists—a class of drugs that mimic a hormone that regulates appetite and blood sugar—have transformed the treatment of obesity and Type 2 diabetes. These medications, originally developed for diabetes, have proven remarkably effective at helping people lose weight.

| Drug | Company | Approval | Primary Use | 2026 Performance |

|------|---------|----------|-------------|-----------------|

| **Wegovy** | Novo Nordisk | 2021 | Obesity | — |

| **Ozempic** | Novo Nordisk | 2017 | Type 2 Diabetes | — |

| **Zepbound** | Eli Lilly | 2023 | Obesity | Q1 2026 sales: ~$4.2 billion |

| **Mounjaro** | Eli Lilly | 2022 | Type 2 Diabetes | Q1 2026 sales: ~$8.7 billion |

Novo Nordisk was first to market with Wegovy, the first GLP-1 approved specifically for weight loss. But Eli Lilly's Zepbound (tirzepatide) has rapidly caught up, with sales reaching nearly $4.2 billion in the first three months of 2026 alone—an 80% increase from the year before. 

### The Head-to-Head Trial That Started It All

The legal battle centers on a clinical trial that Lilly has been using in its advertising. In that trial, Zepbound beat Wegovy in a head-to-head comparison, showing that patients on Zepbound lost an average of 50 pounds compared to 33 pounds on Wegovy. 

**But here's the catch:** that trial compared the highest doses of Zepbound (10 mg and 15 mg) against **lower doses** of Wegovy (1.7 mg and 2.4 mg).

In March 2026, the FDA approved a **higher, 7.2 mg dose** of Wegovy. That higher dose demonstrated an average weight loss of around **19% (about 47 pounds)** .

Novo Nordisk's argument is simple: Lilly's ads are comparing apples to oranges—or more precisely, comparing the best Lilly has to offer against a less potent version of Novo's drug that is no longer the only option on the market.

---

## The Lawsuit: What Novo Nordisk Is Alleging

### "Outdated, Out-of-Context, and Outright Deceptive"

The lawsuit, which runs to dozens of pages, lays out a detailed case that Lilly's advertising violates federal and state false advertising and unfair competition laws, including the Lanham Act. 

**The key allegations:**

**1. Cherry-Picked Comparisons**

Lilly's ads rely on "intentionally selected outdated studies that compare Lilly's highest doses against lower doses of Novo Nordisk's medicines."

**2. Omission of Critical Context**

The ads "bury or omit critical clinical context" about newer, more effective FDA-approved options, such as the 7.2 mg dose of Wegovy.

**3. No Head-to-Head Comparison**

There is no head-to-head clinical trial comparing the highest doses of these two medicines. Lilly's ads imply that Zepbound is superior to Wegovy across the board, but the data simply doesn't exist to support that claim.

**4. A "Deliberate Pattern" of Misconduct**

The suit alleges that these ads are "not an isolated occurrence but part of Lilly's deliberate and continuing pattern and practice across disease areas of comparing higher doses of Lilly's medicines to lower-dose Novo Nordisk comparator medicines."

### The Specific Ads Under Fire

Novo Nordisk has called out specific Lilly ad campaigns, including one titled "Watch This: Head-to-Head," which began airing in February 2026. 

In one television commercial, Lilly compared the companies' weight-loss drugs, stating that people using Zepbound lost an average of 50 pounds compared to an average of 33 pounds for Wegovy's 2.4 mg dose. 

The lawsuit says the commercial did not share results from a clinical trial that showed patients on a higher dose of Wegovy lost an average of 47 pounds. 

### The Diabetes Front: Mounjaro vs. Ozempic

The lawsuit isn't just about obesity drugs. Novo also alleges that Lilly's ads for Mounjaro (for Type 2 diabetes) are misleading. Lilly's ads compare Mounjaro at its highest dose (15 mg) against a lower dose of Ozempic (1 mg)—even though the FDA approved a higher, 2 mg dose of Ozempic more than four years ago. 

**The result?** Consumers are left with "the inevitable conclusion that Lilly's medicines are superior to Novo's, and that's not accurate," said John Kuckelman, Novo's Group General Counsel. 

---

## Novo Nordisk's Argument: Patients Deserve the Truth

Novo Nordisk has framed the lawsuit as a matter of patient safety and informed consent.

"As new and more effective treatment options become available, people deserve accurate information that reflects the latest scientific evidence and helps them make informed care decisions," Kuckelman said. 

"Healthcare companies have a responsibility to keep their public claims accurate and current — ineffective, fine-print disclaimers do not fix the misleading impression created by major national campaigns."

### The 7.2 mg Dose: Novo's Secret Weapon

The FDA's approval of the 7.2 mg dose of Wegovy in March 2026 is central to Novo's case. That dose demonstrated an average weight loss of about 19% (47 pounds), making it much more competitive with Zepbound. 

But Lilly's ads were already running by then—and they continued to run without acknowledging the new data.

"These high-profile US advertising campaigns create the misleading impression that Lilly's medicines are superior, including by withholding critical scientific evidence about newer, more effective FDA-approved options," Novo said in its complaint. 

### "They've Already Polluted the Water"

Novo sent Lilly a cease-and-desist letter in April, Kuckelman said. Lilly responded not by pulling the ads, but by adding a disclaimer saying that the higher dose of Wegovy "wasn't available at the time of the study."

For Novo, that wasn't enough.

"They've already polluted the water, so to speak, and now it needs to be cleaned up," Kuckelman said. 

---

## Eli Lilly's Position: "The Science Speaks for Itself"

As of the time of the lawsuit filing, Lilly had not publicly responded to the allegations. But the company's position is likely to be straightforward: the head-to-head trial data is real, the results are valid, and the ads accurately reflect what the study found.

Lilly may also argue that the 7.2 mg dose of Wegovy was not available at the time of the study, and that its ads appropriately disclose that limitation. The company could also point out that its ads have been reviewed and approved by regulatory bodies.

**But Novo counters** that the ads create a misleading impression regardless of disclaimers. "Ineffective, fine-print disclaimers do not fix the misleading impression created by major national campaigns."

---

## The Stakes: A $120 Billion Market on the Line

The lawsuit comes at a pivotal moment in the pharmaceutical industry. The global obesity market is on track to reach **$120 billion a year by 2030**, according to Bloomberg Intelligence. 

| Competitor | Approach | Status |

|------------|----------|--------|

| **Eli Lilly** | Aggressive DTC advertising; price competition | Market leader in sales |

| **Novo Nordisk** | Legal action; new high-dose Wegovy; oral pill | Fighting to regain share |

| **Pfizer, Merck, others** | Developing new GLP-1 drugs | Entering market |

Novo Nordisk was first to market, but Lilly's Zepbound has surged ahead in sales. Novo has been fighting back with a new high-dose Wegovy, a weight-loss pill, and strategic price cuts. But the advertising battle is the most visible front in this war.

### The Impact on Investors

Both companies' stocks have been volatile. Novo shares fell as much as 1.6% in Copenhagen on the day of the lawsuit, while Lilly shares dipped 0.6% in premarket trading. 

**For Novo**, the lawsuit is a defensive move to protect market share. If successful, it could force Lilly to pull ads that have been driving patients to Zepbound. But the legal process could take years.

**For Lilly**, the lawsuit is an attack on its most successful marketing campaign. A loss could force the company to retract ads and launch corrective advertising, potentially damaging Zepbound's momentum.

---

## What This Means for Patients

### The Human Cost of Misleading Advertising

For the millions of Americans with obesity and Type 2 diabetes, the stakes are personal. GLP-1 medications are life-changing—and the choice between them matters.

Novo argues that Lilly's ads "deprive consumers of the truthful, current, and complete information they need to make informed decisions about their health."

Patients see a 50-pound weight loss claim and choose Zepbound, not realizing that a higher dose of Wegovy might have delivered comparable results. 

"People deserve evidence-based, up-to-date information they can trust when making decisions about their health," Novo said. 

### The Medicare Angle

The timing of the lawsuit is also significant. On July 1, 2026, the Centers for Medicare and Medicaid Services launched the **Medicare GLP-1 Bridge program**, which makes popular weight-loss drugs available to millions of older adults for a $50 monthly copay. 

With more patients gaining access to these drugs, the stakes of misleading advertising are even higher. Misleading ads could steer millions of Medicare beneficiaries toward one drug over another based on incomplete information.

---

## The Broader Context: Pharma's Advertising Wars

The Novo-Lilly lawsuit is the latest escalation in a broader trend of pharmaceutical companies fighting over advertising claims.

### The Lanham Act: Pharma's Legal Weapon

Novo is relying on the Lanham Act, a federal law that prohibits false advertising. Pharmaceutical companies have used this law in the past to challenge competitors' claims—but rarely in such a high-profile, high-stakes context.

### The Hims & Hers Precedent

Earlier this year, Novo sued Hims & Hers Health over compounded versions of its weight-loss drugs. The companies later reached a distribution deal. 

That case showed that Novo is willing to use litigation to protect its turf. But the Lilly lawsuit is on a much larger scale—and the outcome could set a precedent for how pharmaceutical companies advertise GLP-1 drugs.

### The Regulatory Context

Novo may also pursue remedies through the FDA. The agency regulates prescription drug advertising and could take action if it determines that Lilly's ads violate its guidelines.

---

## The Science: What the Data Actually Shows

To understand the lawsuit, you need to understand the data behind the claims.

### Zepbound's Head-to-Head Advantage

In the head-to-head trial, Zepbound showed average weight loss of about **50 pounds**, compared to **33 pounds** for Wegovy (at the 2.4 mg dose).

### Wegovy's High-Dose Data

But the 7.2 mg dose of Wegovy, approved in March 2026, showed average weight loss of about **19% (47 pounds)** .

| Drug | Dose | Average Weight Loss |

|------|------|---------------------|

| **Zepbound** | 10/15 mg | ~50 pounds |

| **Wegovy (old data)** | 1.7/2.4 mg | ~33 pounds |

| **Wegovy (new dose)** | 7.2 mg | ~47 pounds |

The gap between Zepbound and the higher dose of Wegovy is much smaller—from 17 pounds to just 3 pounds.

### The Missing Head-to-Head Trial

**Crucially, there is no head-to-head clinical trial comparing the highest doses of these two medicines.** Lilly's ads imply that Zepbound is superior to Wegovy across the board, but that claim hasn't been tested in a clinical trial.

Novo's argument is that Lilly is presenting its drug as superior when the only evidence that exists compares higher doses of Zepbound to **lower** doses of Wegovy.

---

## What Novo Is Asking For

Novo is seeking several forms of relief:

**1. A Permanent Injunction** requiring Lilly to pull its misleading advertising across all platforms. 

**2. A Corrective Advertising Campaign** to "clean up" the misleading impressions created by Lilly's ads. 

**3. Financial Damages** for the harm caused to Novo's business. 

Novo says that "Lilly's false and misleading advertising diverts patient demand and prescriptions from Novo Nordisk's medicines to Lilly's medicines."

### The Preliminary Injunction

If Lilly does not voluntarily remove the ads, Novo plans to file a formal motion seeking a preliminary injunction to block them immediately while the case proceeds. 

---

## Frequently Asked Questions

### Q: What is Novo Nordisk accusing Eli Lilly of?

Novo Nordisk has filed a lawsuit alleging that Eli Lilly's advertising for its weight-loss and diabetes drugs Zepbound and Mounjaro is false and misleading. The suit claims Lilly uses "outdated studies" that compare the highest doses of Lilly's medicines against "lower doses" of Novo's medicines, creating a misleading impression that Lilly's drugs are superior. 

### Q: Which drugs are involved in the lawsuit?

The lawsuit involves four GLP-1 medications: **Zepbound and Mounjaro** (Eli Lilly) and **Wegovy and Ozempic** (Novo Nordisk). 

### Q: What is the "outdated" data that Novo is complaining about?

Novo says Lilly's ads rely on a head-to-head trial that compared Zepbound at its highest doses to **lower doses** of Wegovy (1.7 mg and 2.4 mg). Novo argues that Lilly's ads should also include data from the **higher 7.2 mg dose of Wegovy**, which was approved by the FDA in March 2026 and showed weight loss of about 19% (47 pounds).

### Q: What is Novo asking the court to do?

Novo is seeking a permanent injunction requiring Lilly to pull its misleading advertising across all platforms and to conduct a corrective advertising campaign. It is also seeking financial damages. 

### Q: Has Lilly responded to the lawsuit?

As of the time of the lawsuit filing, Lilly had not publicly responded. 

### Q: How does this affect patients?

Novo argues that Lilly's ads "deprive consumers of the truthful, current, and complete information they need to make informed decisions about their health."The lawsuit could lead to more accurate advertising of GLP-1 drugs.

### Q: What is the Medicare GLP-1 Bridge program?

Launched on July 1, 2026, this Medicare pilot program makes weight-loss drugs available to eligible enrollees for a $50 monthly copay. 

### Q: What are the potential outcomes of the lawsuit?

Possible outcomes include: Lilly voluntarily pulling or modifying its ads; a court order requiring Lilly to pull the ads and launch corrective advertising; a settlement between the two companies; or the lawsuit being dismissed.

---

## Conclusion: The Battle for the Weight-Loss Market

Novo Nordisk's lawsuit against Eli Lilly is more than just a corporate squabble—it's a fight for the hearts, minds, and prescriptions of millions of Americans living with obesity and Type 2 diabetes.

**The stakes couldn't be higher.** The GLP-1 market is projected to reach $120 billion annually by 2030. The companies that dominate this market will shape the future of obesity treatment for a generation.

Novo's lawsuit alleges that Lilly has gained its lead through "deceptive" advertising that misleads patients into believing Zepbound is superior to Wegovy—without disclosing that the comparison is based on outdated data. 

Lilly, for its part, is likely to argue that its ads accurately reflect the head-to-head trial data and that patients deserve to know the results.

**For patients**, the lawsuit is a reminder to ask questions and seek full information when choosing a GLP-1 medication. The difference between 33 pounds and 47 pounds of weight loss—or between 47 pounds and 50 pounds—could be significant.

**For investors**, the lawsuit introduces uncertainty into the GLP-1 market. A victory for Novo could force Lilly to retract its most effective marketing campaigns. A victory for Lilly could validate its advertising strategy and further cement its lead.

**For the pharmaceutical industry**, the lawsuit could set a precedent for how GLP-1 drugs are advertised. If Novo wins, it could force pharmaceutical companies to be more careful about comparing their drugs to competitors' older, less-effective doses.

As Novo's general counsel put it: "They've already polluted the water, so to speak, and now it needs to be cleaned up."

The question now is whether the courts—or the market—will agree.

---

## Disclaimer

**IMPORTANT:** This article is for informational and educational purposes only and does not constitute medical, legal, or financial advice. The information contained herein is based on publicly available sources and reflects the author's understanding as of the publication date. The lawsuit is ongoing, and the allegations have not been proven in court. GLP-1 medications are prescription drugs that should only be taken under the supervision of a qualified healthcare provider. Individual results may vary. You should consult with your doctor or other qualified healthcare professional before starting, stopping, or changing any medication, and with a qualified attorney or financial advisor regarding any legal or investment matters.

--Read more-

*Published: July 21, 2026*

---

**Tags:** Novo Nordisk, Eli Lilly, GLP-1 lawsuit, deceptive advertising, Wegovy, Ozempic, Zepbound, Mounjaro, weight loss drugs, false advertising, pharmaceutical lawsuit, Lanham Act, obesity treatment, Type 2 diabetes, Medicare GLP-1 Bridge, Zepbound vs Wegovy, Mounjaro vs Ozempic, semaglutide, tirzepatide, pharmaceutical marketing, drug advertising, NVO stock, LLY stock

The Ultimate Outdoor Smart Dimmer: Minoston's Z-Wave 800 Plug Brings Voice Control to Your Backyard

 The Ultimate Outdoor Smart Dimmer: Minoston's Z-Wave 800 Plug Brings Voice Control to Your Backyard

**Weatherproof, voice-controlled, and built to last—this is the smart plug that finally makes outdoor automation effortless.**

---

## Introduction: Take Your Smart Home Outside

You've automated your living room lights. You've set up smart thermostats and security cameras. But your backyard, patio, and garden have been left in the dark ages. Until now.

The **Minoston Z-Wave Plug 800 Outdoor Dimmer (MP22ZD)** is the smart plug that bridges the gap between your indoor smart home and your outdoor spaces. It's rugged, weatherproof, and ready to give you voice control over everything from string lights to fountains to holiday decorations.

**"Alexa, set the patio lights to 75%."** It's that simple.

--for more information-

## Why This Outdoor Dimmer Is a Game-Changer

### 0-100% Dimming by Voice

This isn't just an on/off switch. The Minoston MP22ZD lets you dim your outdoor lights from 0 to 100% using simple voice commands. Want a soft glow for a quiet evening? Just say, "Alexa, set the string lights to 30%." Need bright light for grilling? "Alexa, set the lights to 100%." The control is seamless and intuitive.

### Z-Wave LR 800 Technology

At the heart of this plug is the **Z-Wave 800 series chip**—the latest and greatest in Z-Wave technology. What does that mean for you?

- **Enhanced range**: Up to **1,300 feet** in open range when using Z-Wave LR (Long Range). That's enough to reach from your hub to the far end of your yard.

- **Better power efficiency**: Lower power consumption means less drain on your network.

- **Advanced security**: S2 security protocols protect your devices from unauthorized access.

- **Improved communication**: Faster, more reliable signals that don't drop out.

### Built Tough: IP65 Weatherproof

Rain, snow, dust, and extreme temperatures—this plug handles it all. With an **IP65 weatherproof rating**, it's designed to withstand the elements. Whether it's mounted on your porch, tucked into your garden, or hanging in your garage, this plug is built to last.

### Works with Your Smart Home

The Minoston MP22ZD is compatible with a wide range of Z-Wave hubs:

| Platform | Compatibility |

|----------|---------------|

| **SmartThings** | Yes |

| **Hubitat** | Yes (change device type) |

| **Wink** | Yes |

| **Vera** | Yes |

| **Fibaro** | Yes |

| **HomeSeer** | Yes |

| **2GIG** | Yes |

| **Amazon Alexa** | Yes (with Z-Wave hub) |

| **Google Assistant** | Yes (with Z-Wave hub) |

**Important note:** This plug requires a Z-Wave certified hub to function. It does not connect directly to Wi-Fi or to the Echo Plus.

### Schedule and Timer

Set it and forget it. The plug supports automatic timers and schedules. Your landscape lighting can turn on at sunset and off at sunrise. Your holiday lights can dazzle on a schedule. You'll never leave outdoor lights on accidentally and waste energy.

---

## Perfect for Every Outdoor Space

The Minoston MP22ZD is versatile enough for virtually any outdoor application:

| Use Case | Examples |

|----------|----------|

| **Entertainment** | Patio string lights, deck lighting, party decorations |

| **Landscaping** | Garden lights, pathway lighting, fountains, pumps |

| **Holiday Decor** | Christmas lights, seasonal displays, inflatables |

| **Convenience** | Electric grills, outdoor heaters, pool equipment |

| **Indoor Use** | Basements, garages, workshops, kitchens, bathrooms |

-

--

## What You Need to Know: Important Specs

| Feature | Detail |

|---------|--------|

| **Model** | MP22ZD |

| **Z-Wave Frequency** | 908.42 MHz |

| **Weatherproof Rating** | IP65 |

| **Dimmable Load Max** | 400W Incandescent / 150W LED/CFL |

| **Standard Load Max** | 1875W (15A) |

| **Voltage** | 125V AC |

| **Material** | Polycarbonate (PC) |

| **Connector Type** | Plug In |

| **Certifications** | FCC, ETL listed |

---visit look & buy

## Frequently Asked Questions

### Q: Do I need a hub for this plug?

A: Yes. The Minoston MP22ZD requires a Z-Wave certified hub to function. It does not connect directly to Wi-Fi or to the Echo Plus.

### Q: Can I use this with Alexa or Google Assistant?

A: Yes—**if you have a compatible Z-Wave hub**. With a hub, you can control the plug with voice commands via Alexa or Google Assistant.

### Q: Is this plug truly waterproof?

A: It has an **IP65 weatherproof rating**, meaning it's protected against dust and water jets. It can withstand rain and snow, but it should be hung vertically to ensure the waterproof function works properly.

### Q: What can I plug into it?

A: You can connect a wide range of devices: string lights, landscape lighting, fountain pumps, electric grills, Christmas decorations, and more. Just make sure the total load doesn't exceed the maximum power rating.

### Q: What is the maximum power for dimmable loads?

A: For dimmable loads: **400W for incandescent bulbs** and **150W for LED/CFL bulbs**. Make sure your lights are dimmable and the total power is under the limit.

### Q: What's the difference between Z-Wave 800 and older Z-Wave versions?

A: The 800 series offers enhanced range (up to 1,300 feet in open space), better power efficiency, improved communication protocols, advanced security (S2), and greater network capacity.

---

## Conclusion: Bring the Smart Home Revolution Outside

The Minoston Z-Wave Plug 800 Outdoor Dimmer is the smart plug that outdoor enthusiasts and smart home lovers have been waiting for. It's rugged enough to handle the elements, smart enough to integrate with your favorite platforms, and flexible enough to control virtually any outdoor device.

**Voice-controlled dimming. Weatherproof construction. Seamless integration.** If you've been looking for a way to bring the convenience of your smart home to your backyard, this is the device that makes it happen.

---

## Disclaimer

**IMPORTANT:** This article is a sponsored marketing post promoting the Minoston Z-Wave Plug 800 Outdoor Dimmer. The information provided is based on the manufacturer's description and general product knowledge. Individual experiences may vary. This plug requires a Z-Wave hub and does not connect directly to Wi-Fi or to Echo Plus. Always verify product specifications, compatibility with your specific smart home hub, and local electrical codes before purchase. We encourage readers to read all product details and reviews before making a purchasing decision.

---

*Published: July 21, 2026*

--know more-

**Tags:** Z-Wave outdoor dimmer, smart plug, Minoston MP22ZD, Z-Wave 800, voice control dimmer, outdoor smart plug, weatherproof smart plug, SmartThings compatible, Alexa smart plug, Google Assistant smart plug, patio string lights, landscape lighting, holiday lights, IP65 smart plug